No commercial rubber trees grow in the United States


FACT:  No commercial rubber trees grow in the United States.

THE NUMBERS: Imports of goods by industry type (2024)* –

Industry type 
Import value
Share of Imports

All identifiable U.S. importers
$2.925 trillion
89%

… Manufacturers 
$1.220 trillion
37%

… Wholesalers 
$0.971 trillion
29%

… All known others 
$0.735 trillion
22%

All else, not identified by importer type
$0.370 trillion
11%

Census Bureau.

WHAT THEY MEAN: 

As legal devices, the Trump administration’s tariff decrees are faring poorly. The Supreme Court killed most of Plan A — “emergency” declarations under the International Emergency Economic Powers Act — in February. The specialized Court of International Trade found Plan B, a Section 122 claim that the U.S. is in the midst of a “balance of payments crisis,” illegal last Thursday: 

“Because the Proclamation’s use of trade and current account deficits to stand in the place of balance-of-payment deficits within the meaning of the statute renders the Proclamation ultra viresProclamation No. 11012 is invalid, and the tariffs imposed on Plaintiffs are unauthorized by law.”
Plan C, announced in March and probably going live in July, disinters a third old trade law (“Section 301”), hoping to use it to impose tariffs on allegations of “structural excess capacity” and forced labor law. (PPI’s unimpressed comment here.) Court rulings on this one will presumable coming next year. In the interim, a reality check: if the administration’s decrees are struggling as a legal matter, are they nonetheless achieving their real-world economic goals? 

A year ago, the administration said that while tariff increases might cause pain, this would be transitory. Though prices might go up, and living standards for American waitresses, teachers, truck drivers, and auto mechanics might fall, new manufacturing output and jobs would compensate with better opportunities. A year later, this hasn’t happened: manufacturers have shed about 100,000 jobs, and their “GDP” share is down from 9.8% to 9.4%. Why not? A likely explanation is that the administration’s mental picture of both “trade” and “manufacturing” was naïve: manufacturers are far larger importers than it realized, and a lot of the tariff burden has fallen on them. Two examples, then the big-picture point:

  1. Metal tariffs and container chassis-making: Sitting next to PPI’s Ed Gresser at the U.S. Trade Representative Office’s “public hearing” on Plan C last Friday, a lawyer for U.S.-based makers of container chassis for trucks argued that foreign chassis-makers are getting various tax breaks and other supports from their governments, and unfairly competing to sell the low-priced result to American trucking companies, so tariffs on Chinese-made chassis have simply shifted production to other countries.

Whether or not foreign chassis have gotten too cheap, the administration’s tariff decrees are definitely making the U.S.-made version more expensive. Last June’s “Section 232” tariff decree — not legally challenged so far, and thus fully in force — imposed a 50% tariff on steel on “national security” grounds. According to the Commerce Department, American buyers of steel now pay an average of $971 per ton for their metal, more than twice the $460 average their overseas competitors pay. A 40-foot container chassis costing about $25,000 requires about three tons of steel, and this price gap means the U.S. version now starts out $1,500 in the hole against foreign rivals — even before the potential Plan C tariffs on screws, coatings, rivets, lathes, sandblasters, gantry welders, laser cutters, positioning tables, etc., and all the inputs and capital equipment needed to make things out of metal.

  1. Natural rubber tariffs and airplane tire-making: The March “Federal Register Notice” announcing Plan C cites a “trade surplus in rubber” as grounds for putting Thailand on its 16-country investigation list. Thailand does indeed have such a surplus, but this is natural — in economic terms, a consequence of Southeast Asia’s “absolute advantage” in rubber trees — and a Plan C tariff on Thai rubber would help nobody and harm lots of American manufacturers.

To explain, the U.S. uses about 3 million tons of rubber a year. This includes 1 million tons of natural rubber produced by rubber-tree tapping, and 2 million tons of artificial rubber produced in factories. They aren’t substitutes for one another: artificial rubber is less chemically active and therefore preferred for gaskets, fan belts, tubes, and the soles of shoes; natural rubber, being stretchier and more friction-resistant, is the main material for airplane and truck tires, as well as for condoms, surgical gloves, construction joints, and medical devices.  

All natural rubber comes from abroad — mainly Southeast Asia, secondarily West Africa — because the rubber tree, Hevea brasiliensis, is a tropical plant which thrives in hot, rainy climates. (Curious D.C. Metro residents can see one in the U.S. Botanical Gardens’ climate-controlled Tropics Room near the Capitol.) Since rubber trees don’t grow in places with cold winters, the U.S. produces no natural rubber at all. Tariffs on natural rubber, no matter how high, won’t bring rubber-tree plantation jobs to Minnesota or North Carolina, but will raise costs and reduce sales for every U.S. manufacturer of airplane and truck tires, vibration dampers in bridges, specialized medical equipment, and so on.

These specific cases illustrate a systematic administration error: a belief that “trade” operates on something like 19th-century terms, with manufacturers buying raw materials, farmers and miners exporting bulk commodities, and countries competing to export finished manufactured goods. This wasn’t exactly true then, and hasn’t been close to reality since the 1950s. Just-in-time delivery, supply chains, and coordinated production mean the largest amount of trade is in “intermediate” goods — neither raw materials nor finished stuff, but parts and components used to assemble more complex things. The largest U.S. importers are accordingly not “buyers of finished goods” such as retail chains, hospitals, construction firms, restaurants, and so forth. Instead, they are the chassis-makers buying metals, the airplane-tire-makers buying natural rubber, and other manufacturers buying energy, paint, screws, semiconductor chips, etc., so as to turn these “inputs” into final products or “semi-finished goods” they then sell to others. So though tariffs on steel may benefit steel companies, those benefits only come at the expense of chassis-makers and other metal-users; and tariffs natural rubber are pure losses for U.S. manufacturing.

Statistically, the Census’s annual “Profile of Importing and Exporting Companies” release last Tuesday credits manufacturers with $1.2 trillion in imports — over 40% of the total import value they could identify by industry. That suggests last year’s tariff decrees likely hit U.S. manufacturers with $150 billion or so in new costs. So as the tariffs raised prices for the waitresses, teachers, truck operators, and repair-shop mechanics, they also made it more expensive to operate factories in the United States. Thus no industrial boom has materialized.

In sum: So far, legal judgments on the administration’s tariff decrees haven’t been positive. Real-world economic impacts, likewise.

FURTHER READING

PPI’s four principles for response to tariffs and economic isolationism:

  • Defend the Constitution and oppose rule by decree;
  • Connect tariff policy to growth, work, prices and family budgets, and living standards;
  • Stand by America’s neighbors and allies;
  • Offer a positive alternative.

Data:

Census counts U.S. importers and exporters by industry type, company size, etc., as of 2024 (see Table 1d for the importers), and finds that manufacturers are the largest importers.

Legal update:

Plan A: The April 2nd, 2025, “international emergency” decree. Now defunct.

… the Supreme Court’s February 20 ruling striking it down.

Plan A(ii): The June 3, 2025, steel “national security” decree is an exception since it hasn’t so far faced legal challenge and is still in effect.

Plan B: The February 26, 2026, “balance of payments crisis” decree, ruled illegal last week with appeal pending.

… the Court of International Trade’s ruling striking it down last Thursday.

Plan C: The U.S. Trade Representative Office’s “Structural Excess Capacity” investigation, with a gloomy assessment of how “reindustrialization” is going, and a memorably loopy explanation of “Structural Excess Capacity”:

“The Trump Administration’s reindustrialization efforts continue to face significant challenges due to foreign economies’ structural excess capacity and production in manufacturing sectors. Across numerous sectors, many U.S. trading partners are producing more goods than they can consume domestically. This overproduction displaces existing U.S. domestic production or prevents investment and expansion in U.S. manufacturing production that otherwise would have been brought online. In many sectors, the United States has lost substantial domestic production capacity or has fallen worryingly behind foreign competitors.”

PPI’s Gresser testified on the “Plan C” 301 investigation last week. (Quick summary: inconsistent with the statute and a breach of the separation of powers; economically irrational; data unpersuasive and at times irrelevant.)

… and in Monday’s Wall Street Journal (subs. req.)

ABOUT ED

Ed Gresser is Vice President and Director for Trade and Global Markets at PPI.

Ed returns to PPI after working for the think tank from 2001-2011. He most recently served as the Assistant U.S. Trade Representative for Trade Policy and Economics at the Office of the United States Trade Representative (USTR). In this position, he led USTR’s economic research unit from 2015-2021, and chaired the 21-agency Trade Policy Staff Committee.

Ed began his career on Capitol Hill before serving USTR as Policy Advisor to USTR Charlene Barshefsky from 1998 to 2001. He then led PPI’s Trade and Global Markets Project from 2001 to 2011. After PPI, he co-founded and directed the independent think tank ProgressiveEconomy until rejoining USTR in 2015. In 2013, the Washington International Trade Association presented him with its Lighthouse Award, awarded annually to an individual or group for significant contributions to trade policy.

Ed is the author of Freedom from Want: American Liberalism and the Global Economy (2007). He has published in a variety of journals and newspapers, and his research has been cited by leading academics and international organizations including the WTO, World Bank, and International Monetary Fund. He is a graduate of Stanford University and holds a Master’s Degree in International Affairs from Columbia Universities and a certificate from the Averell Harriman Institute for Advanced Study of the Soviet Union.

Read the full email and sign up for the Trade Fact of the Week.

Free Training

Source link

FH Capital to Acquire 75.1 Percent Stake in JinkoSolar US Manufacturing Unit, Expand Solar and BESS Platform – Asia Pacific


FH Capital will acquire 75.1 percent of JinkoSolar’s US manufacturing subsidiary, expand 2 GW solar module capacity, and launch domestic BESS production to strengthen America’s clean energy manufacturing and supply chain.

May 13, 2026. By EI News Network

FH Capital has entered into an agreement to acquire a 75.1 percent majority stake in JinkoSolar’s US manufacturing subsidiary, creating a domestic solar and Battery Energy Storage Systems (BESS) platform anchored by a 2 GW solar module manufacturing facility in the United States. JinkoSolar will retain a 24.9 percent minority stake in the venture.

Following the transaction, FH Capital plans to inject additional expansion capital to at least double the facility’s current solar module production capacity while also launching domestic BESS manufacturing operations. The move is aimed at strengthening US-based clean energy manufacturing amid rising demand for locally sourced solar and storage products and evolving US energy policies.

FH Capital is led by Sanjeev Chaurasia, a renewable energy investment banker with more than two decades of experience. Chaurasia previously served as Managing Director at Credit Suisse, where he co-founded the firm’s renewable energy practice and led JinkoSolar’s 2010 NYSE IPO.

According to Chaurasia, the transaction combines JinkoSolar’s established US manufacturing presence, technology portfolio, and customer network with FH Capital’s investment and operational capabilities to support growing domestic solar and storage demand.

Nigel Cockroft, US General Manager of JinkoSolar, said that the partnership provides strategic direction and ownership support to expand manufacturing capacity and serve increasing demand for US-sourced renewable energy products.

The transaction remains subject to customary regulatory approvals and closing conditions. Financial details of the deal were not disclosed.

Free Training

Source link

Switzerland-Based Novartis Breaks Ground on Radioligand Therapy Site in Denton » Dallas Innovates



Swiss global pharmaceutical giant Novartis recently broke ground on its new radioligand therapy (RLT) manufacturing site in Denton, part of its broader $23 billion investment in U.S. manufacturing and research.

When completed in 2028, the company’s first Texas‑based manufacturing facility will bring RLT medications closer to patients across the southern United States, becoming the fifth RLT site nationwide, Novartis said.

Novartis CEO Vas Narasimhan said radioligand therapy “is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale.”

“Breaking ground in Denton further strengthens our U.S. supply chain and helps ensure patients can receive these highly personalized treatments when and where they need them,” Narasimhan added in a statement.

The 46,000-square foot facility aims to boost Novartis’ position as the first company to deliver RLT at scale, creating the network capacity needed as these therapies extend into earlier stages of treatment and a broader range of cancers. Announced earlier this year, the Denton facility is expected to create new U.S.-based Novartis jobs in bioengineering, advanced manufacturing, quality, and operations, supporting economic growth in Denton and surrounding communities, the company said. 

Swiss ambassador, U.S. Department of Commerce official took part in groundbreaking 

Taking part in the groundbreaking in Denton were U.S. Under Secretary of Commerce for Industry and Security Jeffrey Kessler; Swiss Ambassador to the U.S. Ralf Heckner; Texas State Senator Brent Hagenbuch; Texas State Representative Andy Hopper; and Denton Mayor Gerard Hudspeth. They joined Novartis leadership, employees, and community partners to celebrate the start of construction.

“I’m pleased to welcome Novartis to Denton as their newest manufacturing location for their cancer therapies,” Texas State Senator Brent Hagenbuch said in a statement. “Their decision establishes a strong partnership and reflects the unique opportunity Denton provides to a well-educated workforce, and the unique access the new plant location will provide to the vibrant North Texas economy and rapidly growing state population.”

Producing medications for U.S. patients in the U.S.

The Texas facility strengthens the Novartis coast-to-coast RLT manufacturing network, with existing US sites in New Jersey, Indiana and California, and another new site being added in Florida. Together, the facilities make up the largest U.S. RLT manufacturing network, further bolstering the company’s longstanding track record of enabling over 99% of doses to be administered on the planned day of treatment.

Each dose of RLT is custom-made and requires precise coordination, the company said, making manufacturing reliability and proximity to treatment centers key factors in providing timely treatment.

At the groundbreaking, Kessler said the Trump Administration “is delivering historic wins for the American people—lowering drug prices, revitalizing manufacturing, creating jobs, and attracting massive new investments. Novartis’s groundbreaking today is the latest example of the Administration’s successful policies at work.

In April 2025, Novartis said it was designating $23 billion over five years to grow its U.S. research and manufacturing footprint. Seven new and three expanded facilities across the country are already under construction—part of the company’s goal of manufacturing all key medicines for U.S. patients in the U.S, supporting supply resilience and dependable delivery of medicines.

Don’t miss what’s next. Subscribe to Dallas Innovates.

Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.

 

Free Training

Source link